Literature DB >> 30569178

Early diagnosis of trisomy 21, trisomy 18 and trisomy 13 using nuchal translucency thickness and ductus venosus blood flow waveform in West China.

Ying Tang1, Hong Luo1, Dezhi Mu2, Taizhu Yang1, Qi Zhu1, Fan Yang1, Guanjian Liu3.   

Abstract

Abnormal nuchal translucency (NT) thickness and ductus venosus (DV) blood flow have been associated with trisomy 21, 18 and 13. However, the association of abnormal DV with these aneuploidies varies among clinical studies. The present study examined the possibility of using NT combined with DV for the early diagnosis of the three aforementioned aneuploidies in the Western Chinese population, focusing on three aspects: Biological pathway analysis, theoretical statistical analysis and clinical data analysis from 1,962 first‑trimester pregnant women from Western China. The pathway and statistical analyses performed suggested the reliability of integrating NT and DV in the prediction of the three aneuploidies. The clinical data analysis suggested that integrating NT and DV, compared with NT alone, resulted in increased predictive power (34.09 vs. 22.45%), better rejection probability (0.21 vs. 0.44%), increased specificity (96.71 vs. 94.07%) and increased sensitivity (89.47 vs. 80.49%). The present results suggested the reliability of integrating NT and DV for the early diagnosis of trisomy 21, 18 and 13 for the Western Chinese population. The present results provided novel statistical analyses to the field of prenatal diagnosis in the Western Chinese population.

Entities:  

Mesh:

Year:  2018        PMID: 30569178     DOI: 10.3892/mmr.2018.9756

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  1 in total

1.  Different Cutoff Values for Increased Nuchal Translucency in First-Trimester Screening to Predict Fetal Chromosomal Abnormalities.

Authors:  Linjuan Su; Xiaoqing Wu; Na Lin; Xiaorui Xie; Meiying Cai; Meiying Wang; Lin Zheng; Liangpu Xu
Journal:  Int J Gen Med       Date:  2021-11-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.